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Colonization with antibiotic-susceptible strains
protects against methicillin-resistant Staphylococcus
aureus but not vancomycin-resistant enterococci
acquisition: a nested case-control study
Susan S Huang1,2*, Rupak Datta1,3, Sheryl Rifas-Shiman3, Ken Kleinman3, Hilary Placzek3,4, Julie D Lankiewicz3 and
Richard Platt2,3
Abstract
Introduction: Harboring sensitive strains may prevent acquisition of resistant pathogens by competing for
colonization of ecological niches. Competition may be relevant to decolonization strategies that eliminate sensitive
strains and may predispose to acquiring resistant strains in high-endemic settings. We evaluated the impact of
colonization with methicillin-sensitive Staphylococcus aureus (MSSA) and vancomycin-sensitive enterococci (VSE) on
acquisition of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE),
respectively, when controlling for other risk factors.
Methods: We conducted a nested case-control study of patients admitted to eight ICUs performing admission and
weekly bilateral nares and rectal screening for MRSA and VRE, respectively. Analyses were identical for both
pathogens. For MRSA, patients were identified who had a negative nares screen and no prior history of MRSA. We
evaluated predictors of MRSA acquisition, defined as a subsequent MRSA-positive clinical or screening culture,
compared to those with a subsequent MRSA-negative nares screen within the same hospitalization. Medical
records were reviewed for the presence of MSSA on the initial MRSA-negative nares screen, demographic and
comorbidity information, medical devices, procedures, antibiotic utilization, and daily exposure to MRSA-positive
patients in the same ward. Generalized linear mixed models were used to assess predictors of acquisition.
Results: In multivariate models, MSSA carriage protected against subsequent MRSA acquisition (OR = 0.52, CI: 0.29,
0.95), even when controlling for other risk factors. MRSA predictors included intubation (OR = 4.65, CI: 1.77, 12.26),
fluoroquinolone exposure (OR = 1.91, CI: 1.20, 3.04), and increased time from ICU admission to initial negative swab
(OR = 15.59, CI: 8.40, 28.94). In contrast, VSE carriage did not protect against VRE acquisition (OR = 1.37, CI: 0.54,
3.48), whereas hemodialysis (OR = 2.60, CI: 1.19, 5.70), low albumin (OR = 2.07, CI: 1.12, 3.83), fluoroquinolones (OR
= 1.90, CI: 1.14, 3.17), third-generation cephalosporins (OR = 1.89, CI: 1.15, 3.10), and increased time from ICU
admission to initial negative swab (OR = 15.13, CI: 7.86, 29.14) were predictive.
Conclusions: MSSA carriage reduced the odds of MRSA acquisition by 50% in ICUs. In contrast, VSE colonization
was not protective against VRE acquisition. Studies are needed to evaluate whether decolonization of MSSA ICU
carriers increases the risk of acquiring MRSA when discharging patients to high-endemic MRSA healthcare settings.
This may be particularly important for populations in whom MRSA infection may be more frequent and severe
than MSSA infections, such as ICU patients.
* Correspondence: sshuang@uci.edu
1Division of Infectious Diseases and Health Policy Research Institute,
University of California Irvine School of Medicine, 100 Theory, Ste 110, Irvine,
CA 92697, USA
Full list of author information is available at the end of the article
Huang et al. Critical Care 2011, 15:R210
http://ccforum.com/content/15/5/R210
© 2011 Huang et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant enteroccoci (VRE) cause substan-
tial morbidity and mortality in hospitalized populations
[1-6]. Patients acquiring MRSA or VRE incur significant
risks of subsequent infection. Up to 11% of MRSA-colo-
nized in-patients develop MRSA disease during their
hospital stay, and this risk can approach 30% in the cri-
tically ill [7-9]. Similarly, 19% of VRE-colonized patients
in the intensive care unit (ICU) develop VRE infection
during hospitalization, and this risk can approach 32%
in those with transplants or cancer [10-12]. Risks of
MRSA and VRE infection after colonization also extend
into the post-discharge setting. We previously found
that 29% of MRSA carriers and 8% of VRE carriers
developed invasive disease within 18 months, with post-
discharge MRSA and VRE infections often requiring
readmission [13-15].
Importantly, compared to MSSA colonization, MRSA
colonization is associated with a four-fold increase in
infection risk [16]. Even after controlling for host risk
factors, it has been shown that MRSA colonized-patients
are more likely to develop subsequent infection com-
pared to MSSA-colonized patients [17]. These differen-
tial risks of infection following colonization are
important since MRSA bacteremia is associated with
greater attributable morbidity and mortality compared
to MSSA bacteremia [2,3,18]. Moreover, the increased
mortality associated with MRSA versus MSSA extends
up to three months after hospital discharge [19].
Given these risks, many studies have evaluated predic-
tors of MRSA and VRE acquisition to improve infection
prevention methods. Most predictors of MRSA acquisi-
tion have related to host comorbidities, hospital factors,
and antimicrobial use. For instance, diabetes, hemodialy-
sis, ulcers, trauma, ICU stays, admission to surgical
ICUs, and antibiotic exposure are known to predispose
to MRSA colonization [20-26]. Although VRE carriage
more commonly occurs in the critically ill, similar risk
factors exist for VRE acquisition including immunosup-
pression, neutropenia, hematologic malignancies, ICU
admission, and antibiotic exposure [27-32]. Environmen-
tal contamination has also been associated with MRSA
and VRE acquisition [33-39].
Although predictors of MRSA and VRE colonization
have been well documented, less is known about protec-
tive factors. It has been hypothesized that methicillin-
sensitive Staphylococcus aureus (MSSA) and other anti-
biotic-sensitive bacteria may protect against MRSA
acquisition by competing for colonization of the anterior
nares [40]. Competition may be relevant to decoloniza-
tion strategies that may eliminate MSSA and predispose
to MRSA acquisition in high endemic settings such as
ICUs and nursing homes. Therefore, we assessed
whether MSSA or vancomycin-sensitive enterococci
(VSE) colonization reduces the risk of MRSA and VRE
acquisition, respectively.
Materials and methods
We conducted a retrospective nested case-control study
of patients admitted to eight adult ICUs between 1 Sep-
tember 2003 and 30 April 2005 at a 750-bed academic
medical center in Boston, Massachusetts, who were not
previously known to have MRSA or VRE and who had
MRSA-negative or VRE-negative surveillance cultures
upon ICU admission. All ICUs performed high-compli-
ance admission and weekly surveillance bilateral nares
cultures for MRSA and rectal cultures for VRE, provid-
ing a systematic method to distinguish between
imported and incident cases during endemic conditions.
ICUs included medical, cardiac, general surgery, burn/
trauma, cardiac surgery (two units), thoracic surgery,
and neurosurgery units, and each had a 10-bed capacity.
This study was approved by the Institutional Review
Board at the Brigham and Women’s Hospital. A waiver
of informed consent was granted.
We report details regarding the MRSA cohort, but
data collection and analyses were performed identically
for MRSA and VRE. We obtained census information
detailing ICU patients and occupancy dates during the
study period. We identified all patients who had an
MRSA-negative bilateral nares screening culture and no
prior history of MRSA using microbiology laboratory
and infection control records dating back to 1987. We
then identified patients who had either (1) a subsequent
MRSA-negative bilateral nares screening culture (con-
trol) or (2) a subsequent MRSA-positive clinical or
screening culture (case) within the same hospital stay
(Figure 1). Subsequent MRSA screening generally
reflected routine ICU protocol for weekly screening of
ICU patients on a predetermined weekday. From this
cohort, we selected all cases and a random sample of
controls, and variables associated with MRSA acquisi-
tion were evaluated. All MRSA-negative surveillance
cultures were routinely evaluated for the presence of
MSSA, thereby enabling the systematic identification of
MSSA colonization among cases and controls.
For all MRSA and VRE cases and controls, we col-
lected demographic and comorbidity information based
on International Classification of Diseases, Ninth Revi-
sion, Clinical Modification codes from same-hospital
admissions within one year prior to the initial negative
surveillance culture. Measured comorbidities included
diabetes, end-stage renal disease, end-stage liver disease,
solid cancers, and hematologic malignancies, which were
confirmed by medical chart review. Malignancies were
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recorded only if there was evidence of treatment in the
preceding year. We also identified risk factors for MRSA
and VRE infection during the two weeks prior to the
initial negative surveillance culture through the period
encompassing the subsequent negative or positive sur-
veillance or clinical culture. Risk factors included active
wounds and rashes, recent surgery, and non-surgical
procedures including intubation, bronchoscopy, and the
placement of central lines, drains, or tubes. During this
time, we additionally collected laboratory indicators of
renal insufficiency (creatinine > 2) and poor nutrition
(albumin < 2). For the period of time encompassing two
months prior to the initial negative surveillance culture
until the time of the subsequent negative or positive
surveillance or clinical culture, we also recorded antibio-
tic administration data from the following classes: nar-
row and broad-spectrum penicillins, first, second and
third generation cephalosporins, fluoroquinolones, car-
bapenems, aminoglycosides, macrolides, and anti-MRSA
(vancomycin, linezolid, synercid, daptomycin, tigecy-
cline), other MRSA (doxycycline, bactrim, rifampin),
anti-VRE (linezolid, synercid, daptomycin, tigecycline),
or other VRE (doxycycline, nitrofurantoin)antibiotics.
Time from ICU admission to the initial MRSA-negative
culture was also assessed.
Additionally, we assessed colonization pressure,
defined as the sum of the daily number of same ward
MRSA-positive or VRE-positive patients to which
patients were exposed between the initial negative cul-
ture and the subsequent positive or negative culture for
MRSA or VRE. In addition to evaluating colonization
pressure as a total number of daily exposures, we addi-
tionally evaluated colonization pressure as a density of
exposures divided across the number of days spanned
by the initial negative culture and the subsequent posi-
tive or negative culture for MRSA or VRE.
Potential predictors of MRSA or VRE acquisition were
initially assessed using c2 bivariate tests. Variables sig-
nificant in bivariate testing at a level of a < 0.2 were
entered into multivariate generalized linear mixed mod-
els (GLIMMIX, version 9.1; SAS, SAS Institute, Cary,
NC, USA). All bivariate and multivariate analyses
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Figure 1 Identification of methicillin-resistant Staphylococcus aureus (MRSA) cases and controls following intensive care unit (ICU)
admission. All patients were required to have an initial MRSA-negative bilateral nares screening culture. Controls had a subsequent MRSA-
negative screening culture (Interval A) whereas cases had a subsequent MRSA-positive screening or clinical culture (Interval B).
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accounted for clustering by ICU ward. The primary
independent variables of MSSA and VSE carriage were
forced into the final model. All other final model vari-
ables were retained at a = 0.05.
Results
Across a 20-month period, a total of 8,203 patients had
11,528 ICU room stays. Among them, 809 patients and
658 patients were already MRSA and VRE carriers on
ICU admission, leaving 7,629 and 7,806 patients eligible
for MRSA and VRE acquisition, respectively. Of these,
244 and 227 patients acquired MRSA and VRE based
upon a positive culture in patients with a negative sur-
veillance culture and no prior history of MRSA or VRE,
respectively. Cases were compared to a random sample
of 250 controls for each pathogen. Medical records for
two controls were unavailable, resulting in a total of 248
MRSA-negative controls and 248 VRE-negative controls.
Descriptive characteristics of MRSA and VRE cases
and controls are shown in Tables 1 and 2, respectively.
Patient characteristics were similar across MRSA and
VRE cohorts, with half being over 65 years old, nearly
one-third having diabetes and one-quarter with a solid
cancer. The vast majority had recent surgeries or non-
surgical procedures. Compared to controls, MRSA cases
had a significantly longer mean time from ICU admis-
sion to initial MRSA-negative swab (mean 4.9 versus 1.4
days, P < 0.001). Similar results were found for VRE (5.5
versus 1.3 days, P < 0.001).
Table 1 further lists variables associated with MRSA
acquisition in bivariate testing. Harboring MSSA was
protective, while increased time from ICU admission to
initial MRSA-negative swab, intubation, presence of a
central line, fluoroquinolone utilization, and anti-MRSA
antibiotic utilization were significantly associated with
MRSA acquisition. In generalized linear mixed models,
only MSSA carriage, intubation, fluoroquinolone utiliza-
tion, and time from ICU admission to initial MRSA-
negative swab remained associated with MRSA acquisi-
tion (Table 3).
Variables associated with VRE acquisition in bivariate
testing are shown in Table 2. Similar to MRSA,
increased time from ICU admission to initial VRE-nega-
tive swab, intubation, presence of a central line, and
fluoroquinolone utilization were significantly associated
with VRE acquisition. Several other factors were also
associated with VRE acquisition in bivariate testing,
including end-stage renal disease, wounds, rashes, low
albumin, elevated creatinine, colonization pressure and
macrolide, aminoglycoside, third-generation cephalos-
porin and carbapenem utilization. Many of these vari-
ables remained associated with VRE acquisition in
multivariate testing using generalized linear mixed
models (Table 3). However, in contrast to MRSA, VSE
carriage was not associated with VRE acquisition.
Discussion
Among ICU patients from a tertiary care medical center,
we show that MSSA carriage results in a 50% reduced
odds of MRSA acquisition when extensively accounting
for other risk factors. These results support the concept
that various S. aureus strains compete for occupancy of
the anterior nares [40]. In this case, the protective nat-
ure of MSSA likely arises from being the initial occu-
pant of the niche. It is likely that the presence of MRSA
would similarly prevent the establishment of MSSA in
the anterior nares. Thus, the presence or absence of the
mec A gene alone is used as a surrogate means to distin-
guish S. aureus strains, rather than to suggest a compe-
titive advantage in the absence of beta-lactam
antibiotics.
However, regardless of the mechanism for competi-
tion between strains, evidence for competition sup-
ports the need to be judicious in applying
decolonization regimens to eradicate the S. aureus
reservoir. In particular, MSSA carriage may be prefer-
able to the chance for re-colonization with an MRSA
strain in certain high risk patient populations since it
has been suggested in several studies that MRSA infec-
tions produce greater morbidity, mortality, and cost
compared to MSSA infections in case mix-adjusted
patient populations [2,3,16-18,41,42].
These results are relevant to decolonization strategies
that are increasingly used and have been shown to suc-
cessfully reduce MSSA and MRSA infections among
carriers in high-endemic settings, including intensive
care units and patients undergoing surgical procedures
[43-51]. Currently, cardiac surgeons have a national
guideline for pre-operative screening and decolonization
of S. aureus to reduce S. aureus surgical site infections
[43-45]. Increasingly, chlorhexidine and mupirocin are
being routinely applied to MRSA carriers in hospitals to
reduce healthcare-associated MRSA infection
[46,49,52,53].
The large body of evidence demonstrating substantial
benefits of decolonization should be weighed against the
potential of increased MRSA acquisition risk due to a
vacated anterior nares niche. Studies are needed to evalu-
ate whether decolonization of MSSA carriers increases
the risk of acquiring MRSA when discharging patients to
high-endemic MRSA healthcare settings. On the other
hand, we recognize this risk may be mitigated by decolo-
nization which could reduce the prevalence and trans-
mission of MRSA in post-discharge healthcare settings.
Consistent with prior reports, we found that patients
who acquired MRSA and VRE had longer ICU lengths
Huang et al. Critical Care 2011, 15:R210
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Table 1 Bivariate assessment of characteristics associated with methicillin-resistant Staphylococcus aureus (MRSA)
acquisition among cases and controls
Variable Controls a
N (%)
Cases a
N (%)
Odds ratio b
(95% CI)
P-value
Total 248 (100%) 244 (100%)
Age 0.47
< 45 40 (16%) 38 (16%) 1.0, reference
45 to < 55 31 (13%) 26 (11%) 0.93 (0.46, 1.88)
55 to < 65 59 (24%) 54 (22%) 1.12 (0.62, 2.04)
65 to < 75 54 (22%) 68 (28%) 1.56 (0.85, 2.85)
75+ 64 (26%) 58 (24%) 1.10 (0.60, 2.01)
Male gender 146 (59%) 140 (57%) 1.11 (0.77, 1.59) 0.58
Comorbidities
Diabetes mellitus 71 (29%) 70 (29%) 1.07 (0.71, 1.61) 0.76
End-stage renal disease 12 (5%) 20 (8%) 1.67 (0.79, 3.53) 0.18
End-stage liver disease 6 (2%) 12 (5%) 2.20 (0.80, 6.08) 0.13
Solid cancer 63 (25%) 64 (26%) 1.07 (0.67, 1.69) 0.78
Hematologic malignancy 13 (5%) 9 (4%) 0.71 (0.29, 1.75) 0.46
ICU Type 0.26
Medical 82 (33%) 61 (25%) 0.67 (0.33, 1.35)
Surgical 166 (67%) 183 (75%)
ICU admit to negative swab < .0001
1 day 183 (74%) 82 (34%) 1.0, reference
2 days 50 (20%) 41 (17%) 1.81 (1.11, 2.97)
≥ 3 days 15 (6%) 121 (50%) 17.82 (9.77, 32.49)
Active wound 181 (73%) 193 (79%) 1.20 (0.76, 1.89) 0.43
Active rash 30 (12%) 33 (14%) 1.18 (0.69, 2.02) 0.55
Surgical procedures c 207 (83%) 196 (80%) 0.72 (0.45, 1.17) 0.19
Non-surgical procedures c
Intubation 213 (86%) 238 (98%) 6.09 (2.48, 14.94) < .0001
Central line 192 (77%) 214 (88%) 2.10 (1.27, 3.48) 0.004
Arterial line 226 (91%) 232 (95%) 1.78 (0.84, 3.78) 0.13
Chest tube 94 (38%) 86 (35%) 0.87 (0.54, 1.40) 0.57
Surgical drain 108 (44%) 98 (40%) 0.85 (0.57, 1.25) 0.41
Labs c
Albumin < 2 21 (9%) 34 (14%) 1.60 (0.89, 2.88) 0.11
Creatinine > 2 52 (21%) 68 (28%) 1.54 (0.99, 2.37) 0.05
Colonization pressure 0.08
0 9 (4%) 15 (6%) 1.33 (0.52, 3.38)
1 to < 4 72 (29%) 51 (21%) 0.54 (0.33, 0.90)
4 to < 8 66 (27%) 54 (22%) 0.64 (0.39, 1.05)
8 to < 12 42 (17%) 42 (17%) 0.76 (0.44, 1.33)
12+ 59 (24%) 82 (34%) 1.0, reference
Sensitive strain carrier d 49 (20%) 30 (12%) 0.55 (0.33, 0.91) 0.02
Antibiotic utilization c
Aminoglycoside 33 (13%) 24 (10%) 0.71 (0.40, 1.26) 0.24
Clindamycin 20 (8%) 18 (7%) 0.94 (0.48, 1.85) 0.87
Macrolide 26 (10%) 26 (11%) 1.07 (0.59, 1.93) 0.83
Fluoroquinolone 146 (59%) 193 (79%) 2.91 (1.91, 4.42) < .0001
First generation Cephalosporin 101 (41%) 107 (44%) 0.97 (0.65, 1.46) 0.89
Second generation Cephalosporin 3 (1%) 6 (2%) 1.93 (0.47, 8.03) 0.36
Third generation Cephalosporin 72 (29%) 88 (36%) 1.49 (1.01, 2.21) 0.05
Broad spectrum penicillin 0 (0%) 6 (2%)
Carbapenem 6 (2%) 11 (5%) 2.13 (0.76, 5.96) 0.15
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Table 1 Bivariate assessment of characteristics associated with methicillin-resistant Staphylococcus aureus (MRSA)
acquisition among cases and controls (Continued)
Anti-MRSA antibiotics e 159 (64%) 182 (75%) 1.92 (1.26, 2.92) 0.002
Other MRSA antibiotics f 10 (4%) 4 (2%) 0.40 (0.12, 1.31) 0.13
aCases and controls had a negative bilateral nares surveillance swab and no prior history of MRSA upon intensive care unit admission
bAccounted for clustering by intensive care unit ward
cAssessed during the two weeks prior to the initial negative surveillance culture through the period encompassing the subsequent negative or positive
surveillance or clinical culture for MRSA
dSensitive strain refers to methicillin-sensitive Staphyloccocus aureus
eAnti-MRSA antibiotics include vancomycin, linezolid, synercid, daptomycin, and tigecycline
fOther MRSA antibiotics include doxycycline, bactrim, and rifampin
CI, confidence interval.
Table 2 Bivariate assessment of characteristics associated with vancomycin-resistant enterococcus (VRE) acquisition
among cases and controls
Variable Controls a
N (%)
Cases a
N (%)
Odds ratio b
(95% CI)
P value
Total 248 (100%) 227 (100%)
Age 0.98
< 45 24 (10%) 20 (9%) 1.0, reference
45 to < 55 35 (14%) 31 (14%) 0.95 (0.43, 2.08)
55 to < 65 51 (21%) 54 (24%) 1.13 (0.55, 2.35)
65 to < 75 62 (25%) 58 (26%) 1.01 (0.49, 2.08)
75+ 76 (31%) 64 (28%) 0.97 (0.48, 1.98)
Male gender 127 (51%) 139 (61%) 0.72 (0.49, 1.04) 0.08
Comorbities
Diabetes mellitus 72 (29%) 81 (36%) 1.43 (0.95, 2.13) 0.08
End-stage renal disease 15 (6%) 29 (13%) 2.36 (1.21, 4.60) 0.01
End-stage liver disease 11 (4%) 8 (4%) 0.79 (0.31, 2.05) 0.63
Solid cancer 55 (22%) 64 (28%) 1.19 (0.74, 1.89) 0.47
Hematologic malignancy 15 (6%) 18 (8%) 1.16 (0.56, 2.43) 0.69
ICU type 0.77
Medical 92 (37%) 75 (33%) 0.88 (0.37, 2.06)
Surgical 156 (63%) 152 (67%)
ICU admit to negative swab < .0001
1 day 186 (75%) 79 (35%) 1.0, reference
2 days 48 (19%) 30 (13%) 1.46 (0.85, 2.52)
≥ 3 days 14 (6%) 118 (52%) 18.92 (10.23, 34.97)
Active wound 174 (70%) 184 (81%) 1.74 (1.07, 2.83) 0.03
Active rash 21 (8%) 40 (18%) 2.16 (1.22, 3.83) 0.01
Surgical procedures c 218 (88%) 175 (77%) 0.42 (0.25, 0.71) 0.001
Non-surgical procedures c
Intubation 210 (85%) 214 (94%) 2.47 (1.25, 4.90) 0.01
Central line 200 (81%) 212 (94%) 2.99 (1.60, 5.62) 0.001
Arterial line 222 (90%) 211 (93%) 1.44 (0.73, 2.83) 0.29
Chest tube 97 (39%) 93 (41%) 0.79 (0.49, 1.27) 0.32
Surgical drain 106 (43%) 74 (33%) 0.61 (0.40, 0.93) 0.02
Labs c
Albumin < 2 28 (11%) 56 (25%) 2.39 (1.43, 3.98) 0.001
Creatinine > 2 74 (30%) 99 (44%) 2.03 (1.35, 3.05) 0.001
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of stay [35,54,55]. We controlled for comorbidities and
procedures that may have accounted for this and identi-
fied mechanical ventilation, fluoroquinolone exposure,
and increased ICU duration prior to the initial negative
swab as independent predictors of MRSA acquisition
[21,35,56-58]. We also assessed other previously defined
risk factors, but we highlight the protective nature of
MSSA when performing a comprehensive evaluation of
potential factors associated with MRSA acquisition. Our
work indicates that interactions between colonizing S.
aureus strains should be considered when evaluating
patient-level predictors of MRSA acquisition, particu-
larly in the setting of decolonization therapy.
In contrast to the association between MSSA and
MRSA colonization, VSE was not protective against
VRE acquisition. This latter finding is consistent with
the abundance of microbial flora in the gut reservoir,
where antibiotic-susceptible and resistant strains are not
mutually exclusive for intestinal colonization. Similar to
prior papers, we identified several risk factors associated
with VRE acquisition including end-stage renal disease,
active wounds, and low serum albumin levels [59,60].
Our study has important limitations. First, this study
was restricted to ICU patients from a tertiary care hos-
pital, and nearly 90% of our study population underwent
Table 3 Variables associated with methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant
enterococcus (VRE) acquisition
Variable Odds ratio a (95% CI) P Value
MRSA
MSSA carrier 0.52 (0.29, 0.95) 0.03
Intubation 4.65 (1.77, 12.26) 0.002
Fluoroquinolone 1.91 (1.20, 3.04) 0.01
ICU admit to negative swab < .0001
1 day 1.0, reference
2 days 1.97 (1.17, 3.30)
≥ 3 days 15.59 (8.40, 28.94)
VRE
VSE carrier 1.37 (0.54, 3.48) 0.51
End-stage renal disease 2.60 (1.19, 5.70) 0.02
Albumin < 2 2.07 (1.12, 3.83) 0.02
Fluoroquinolone 1.90 (1.14, 3.17) 0.01
Third generation Cephalosporin 1.89 (1.15, 3.10) 0.01
ICU admit to negative swab < .0001
1 day 1.0, reference
2 days 1.42 (0.79, 2.56)
≥ 3 days 15.13 (7.86, 29.14)
aBased on generalized linear mixed model testing
CI, confidence interval.
Table 2 Bivariate assessment of characteristics associated with vancomycin-resistant enterococcus (VRE) acquisition
among cases and controls (Continued)
Colonization pressure < .0001
0 29 (12%) 10 (4%) 0.17 (0.07, 0.38)
1 to < 4 70 (28%) 21 (9%) 0.15 (0.08, 0.27)
4 to < 8 58 (24%) 48 (21%) 0.40 (0.24, 0.67)
8 to < 12 41 (17%) 43 (19%) 0.50 (0.29, 0.87)
12+ 50 (20%) 105 (46%) 1.0, reference
Sensitive strain carrier d 14 (6%) 14 (6%) 1.08 (0.50, 2.34) 0.85
Antibiotic utilization c
Aminoglycoside 24 (10%) 43 (19%) 2.27 (1.31, 3.93) 0.004
Clindamycin 14 (6%) 22 (10%) 1.90 (0.93, 3.88) 0.08
Macrolide 14 (6%) 30 (13%) 2.91 (1.47, 5.76) 0.002
Fluoroquinolone 141 (57%) 182 (81%) 2.94 (1.91, 4.50) < .0001
First generation Cephalosporin 92 (37%) 68 (30%) 0.68 (0.45, 1.04) 0.08
Second generation Cephalosporin 8 (3%) 6 (3%) 0.72 (0.24, 2.15) 0.56
Third generation Cephalosporin 55 (22%) 107 (48%) 3.33 (2.20, 5.05) < .0001
Broad spectrum penicillin 1 (0.40%) 3 (1%) 2.56 (0.26, 25.24) 0.42
Carbapenem 9 (4%) 21 (9%) 2.56 (1.13, 5.79) 0.02
Anti-VRE antibiotics e 3 (1%) 9 (4%) 3.66 (0.95, 14.03) 0.06
Other VRE antibiotics f 2 (0.81%) 3 (1%) 2.01 (0.32, 12.64) 0.46
aCases and controls had a negative rectal surveillance swab and no prior history of VRE upon intensive care unit admission
bAccounted for clustering by intensive care unit ward
cAssessed during the two weeks prior to the initial negative surveillance culture through the period encompassing the subsequent negative or positive
surveillance or clinical culture for VRE
dSensitive strain refers to vancomycin-sensitive enterococci
eAnti-VRE antibiotics include linezolid, synercid, daptomycin, and tigecycline
fOther VRE antibiotics include doxycycline, nitrofurantoin
CI, confidence interval.
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surgery. Due to differences in patient populations, our
findings may not be generalizable to other hospitals or
non-ICU settings. Second, our work was often reliant on
either nares or rectal screening alone to determine
MRSA or VRE acquisition, respectively. If the sensitivity
of these single-site screening tests was low, some of our
controls may have actually harbored MRSA or VRE, and
some of our cases may have actually been long term
carriers. Nevertheless, this would have reduced the dif-
ferences found between the groups. Finally, our results
may not be generalizable to MRSA clones that do not
predominantly colonize the anterior nares. While this
has been suggested for community-associated clones,
other research has found no difference in the strain-spe-
cific distribution of body site carriage among nursing
home residents [61].
Conclusions
We found that MSSA nasal carriage conferred a 50%
reduction in the odds of MRSA acquisition among ICU
patients. In contrast, no protective effect was observed
for VSE. These findings are important for decolonization
regimens that may eliminate MSSA and predispose to
MRSA acquisition in high-endemic settings, such as
ICUs, nursing homes, and rehabilitation centers. Addi-
tional studies are needed to better understand the
degree to which MSSA is protective and the long-term
impact of decolonization relative to subsequent health-
care exposures.
Key messages
• MSSA carriage significantly protects against MRSA
acquisition in ICUs.
• In contrast, VSE carriage does not protect against
VRE acquisition in ICUs.
• Studies are needed to evaluate whether decoloniza-
tion of MSSA ICU carriers increases the risk of
acquiring MRSA when discharging patients to high-
endemic MRSA healthcare settings.
Abbreviations
ICU: intensive care unit; MRSA: methicillin-resistant Staphylococcus aureus;
MSSA: methicillin-sensitive Staphylococcus aureus; VRE: vancomycin-resistant
enterococci; VSE: vancomycin-sensitive enterococcus.
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